Pulmonary Fibrosis Xray When treated with pirfenidone, patients with idiopathic pulmonary fibrosis experienced significant improvements in 6-minute walking distance and University of California San ...
When treated with pirfenidone, patients with idiopathic pulmonary fibrosis experienced significant improvements in 6-minute walking distance and University of California San Diego Shortness of Breath ...
Pirfenidone, an experimental oral antifibrotic agent, appears to be a promising treatment option for patients who have overt diabetic nephropathy. “The dramatic finding of this exploratory study is ...
While both drugs slowed down lung function decline in idiopathic pulmonary fibrosis (IPF), they were also linked to more deaths and increased incidence of acute exacerbation of IPF in real-world ...
Please provide your email address to receive an email when new articles are posted on . Nintedanib plus pirfenidone led to a comparable rate of adverse events as monotherapy. Combination therapy may ...
Researchers compared the cost-effectiveness of ninetedanib to pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) and found nintedanib to be more cost-saving than pirfenidone, ...
The generic version is available in 2 dosage strengths. Sandoz has announced the launch of Pirfenidone tablets, the first AB-rated equivalent to Esbriet ®, for the treatment of idiopathic pulmonary ...
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing ...
Novel oral agent nerandomilast slowed progression of idiopathic pulmonary fibrosis (IPF), even atop background antifibrotic therapy, the phase III FIBRONEER-IPF trial showed. Forced vital capacity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results